welcome to DuchenneXchange- a positively charged Duchenne muscular dystrophy community.
- join today!
Evaluation of Muscle miRNA as Biomarkers in Dystrophinopathies
study id #: NCT02109692
condition: Muscular Dystrophies, Becker Muscular Dystrophy, Duchenne Muscular Dystrophy
Duchenne muscular dystrophy (DMD), caused by mutations in the DMD gene, is the most common and most severe progressive dystrophy of the child. Although the development is rapidly progressive, there is variability in the severity of the disease between DMD patients that do not correlate with the type of mutations in the DMD gene. There are no easily measurable biomarkers for monitoring the DMD or moderate form of the disease, Becker muscular dystrophy (BMD). MicroRNAs (miRNAs) are involved in most cellular processes, and their expression pattern is a signature of the state of a cell. They represent a potential class of diagnostic and prognostic biomarkers. Some are specific for the skeletal myogenesis, and changes in their pattern of expression are associated with muscle diseases including muscular dystrophy. The levels of muscle- specific miRNAs are indeed greatly increased in the serum of DMD and BMD compared to control patients. The main objective of this is to validate the use of serum muscle-derived microRNAs as biomarkers of DMD patients (compared with healthy subjects). Secondary objectives are i) to investigate the relationship between circulating levels of these miRNAs and the severity of the dystrophinopathy (DMD vs BMD) and also the progression of the disease (longitudinal study), ii) to assess the specificity of these markers for dystrophinopathy (comparison with other patients with muscular dystrophy), iii) to test candidate miRNAs recently identified but not yet analyzed in the serum of patients. Clinical data and samples will be recorded at each regular consultation. miRNA levels will be quantified using Real Time Quantitative RT-PCR.
intervention: blood sample
mechanism of action: No pharmaceutical intervention
last updated: November 22, 2018
start date: May 19, 2014
estimated completion: November 2018
phase of development: N/A
size / enrollment: 186
- Quantity of serum muscle-derived microRNAs of DMD patients [Time Frame: up to 12 months]
To validate the use of serum muscle-derived microRNAs as biomarkers of DMD patients (compared with healthy subjects)
- severity of the dystrophinopathy [Time Frame: up to 36 months]
to investigate the relationship between circulating levels of these miRNAs and the severity of the dystrophinopathy
- progression of the disease [Time Frame: up to 36 months]
to investigate the relationship between circulating levels of these miRNAs and the progression of the disease
- specificitiy of miRNA for distrophinopathy [Time Frame: up to 36 months]
to assess the specificity of these markers for dystrophinopathy (comparison with other patients with muscular dystrophy)
• Patient suffers from dystrophinopathy or other muscle dystrophy
• Healthy volunteers
• signed informed consent
• social insurance
patients or parents have not signed the informed consent
Clinical Trial to Evaluate the Efficacy, Safety, and Tolerability of RO7239361 in Ambulatory Boys With Duchenne Musc...This is a multi-center, randomized, doub...
A Clinical Study to Assess Two Doses of GSK2402968 in Subjects With Duchenne Muscular Dystrophy (DMD)The purpose of this study is to determin...
Study of ataluren in previously treated participants with nonsense mutation dystrophinopathy (nmDBMD)The objective of this study is to assess...
Clinical Intramuscular Gene Transfer Trial of rAAVrh74.MCK.Micro-Dystrophin to Patients With Duchenne Muscular Dystr...The proposed phase I clinical trial is a...
A Phase III Double-blind Study With Idebenone in Patients With Duchenne Muscular Dystrophy (DMD) Taking Glucocortico...The purpose of the study is to assess th...
Capricor to Meet with FDA under its RMAT Designation to Discuss HOPE-2 Clinical TrialCapricor Therapeutics announced today th...
Stacking Exercises Aid the Decline in FVC and Sick TimeDuchenne Muscular Dystrophy is complicat...
“Watching time tick by…”: Decision making for Duchenne muscular dystrophy trialsObjective:This interview study explored ...
Duchenne muscular dystrophy: How muscle cells journey to the dark sidePromoting repair of dystrophic muscles i...
DMD clinical therapies II: P.135 DMD-HUB: expanding clinical trial capacity for Duchenne muscular dystrophy, 1 year ...The need to increase capacity for Duchen...
ReveraGen Announces First Patient Enrollment in International Pivotal Trial of Vamorolone in Duchenne Muscular Dystr...ReveraGen BioPharma, Inc. today announce...